Could donor islet cells free diabetics from insulin after kidney transplant?
NCT ID NCT01241864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether transplanting insulin-producing islet cells from deceased donors can help people with type 1 diabetes who have already received a kidney transplant. The goal is to achieve safe blood sugar levels without insulin shots. Ten participants will receive the cells via a vein in the liver and must take immunosuppressant drugs as long as the cells work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Allogenic islet cells (donor pancreas cells) plus immunosuppressant drugs
What this could lead to
If successful, this could help people with type 1 diabetes who have had a kidney transplant achieve near-normal blood sugar without insulin shots, reducing complications.
What could go wrong
This is a very small early-phase trial (10 people) and requires lifelong immunosuppression, which carries risks like infection and organ damage. It may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact